BioneerCorp

Chart & Performance

D1W1MN

P/E

—

P/S

1.22

EPS

—

Div Yield, %

—

Shrs. gr., 5y

3.54%

Rev. gr., 5y

51.95%

Revenues

293.98b

+11.68%

Net income

-20.58b

L+94.43%

CFO

-13.48b

Dividend

Mar 15, 20220.285 KRW/sh

Profile

Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analysis, and magnetic separation services, as well as instruments for conventional PCR, real-time PCR, sample preparation, protein synthesis, centrifuge and vortex mixer, electrophoresis, spectrophotometer, and microbial culture. It also provides molecular diagnosis, including MDx technologies, human diagnostics kits, MDx extraction kits, and instruments; and products for animal diseases and nano-bio products. The company was founded in 1992 and is headquartered in Daejeon, South Korea.

URL

https://www.bioneer.co.kr/

IPO date

Dec 29, 2005

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	293,975,485 11.68%	263,236,803 20.53%	218,394,453 -2.39%
Cost of revenue	270,792,247	226,744,852	176,032,647
Unusual Expense (Income)
NOPBT	23,183,238	36,491,951	42,361,807
NOPBT Margin	7.89%	13.86%	19.40%
Operating Taxes	3,717,024	6,851,604	(1,217,551)
Tax Rate	16.03%	18.78%
NOPAT	19,466,214	29,640,347	43,579,357
Net income	(20,584,198) 94.43%	(10,587,030) -187.66%	12,076,879 -55.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current	46,278,858	30,282,504	19,645,139
Long-term debt	29,612,426	17,156,233	8,224,875
Deferred revenue	2,210,880	10	756,344
Other long-term liabilities	5,702,884	9,962,888	6,726,793
Net debt	(25,648,178)	(52,471,808)	(59,837,251)
Cash flow
Cash from operating activities	(13,476,386)	4,135,856	8,805,263
CAPEX	(12,634,861)	(5,491,491)	(18,523,655)
Cash from investing activities	(21,874,796)	(13,468,343)	(19,148,743)
Cash from financing activities	26,105,833	14,054,749	4,674,171
FCF	1,252,588	28,857,612	(8,529,407)
Balance
Cash	94,258,533	91,833,053	80,034,585
Long term investments	7,280,929	8,077,492	7,672,680
Excess cash	86,840,688	86,748,705	76,787,543
Stockholders' equity	18,038,896	26,156,006	34,818,809
Invested Capital	290,486,605	263,323,565	239,629,587
ROIC	7.03%	11.79%	18.86%
ROCE	7.41%	12.50%	15.21%
EV
Common stock shares outstanding	25,810	25,810	25,810
Price	18,850.00 -43.39%	33,300.00 13.27%	29,400.00 -39.51%
Market cap	486,518,500 -43.39%	859,482,690 13.27%	758,822,555 -38.29%
EV	473,843,481	818,011,713	706,522,644
EBITDA	32,311,058	45,444,779	49,621,003
EV/EBITDA	14.67	18.00	14.24
Interest	3,417,511	1,407,616	647,917
Interest/NOPBT	14.74%	3.86%	1.53%